Replies to post #151234 on Biotech Values

[ghmm]

UTHR:

I would think so, though IV/sub-q held up quite well even with Tyvaso on the market and I believe it was Dr. Rubin who believe an Inhaled therapy would be the best way to treat the disease.

From an investment standpoint I think Oral in other indications may have the biggest potential. UTHR has tried/talked about Remodulin for other uses for some time and I'm not a science guy but a Prostacylin makes some sense in other cardiovascular indications.

Here is a link for some studies UTHR has done for those intersted.
http://clinicaltrials.gov/ct2/results?term=UT-15&Search=Search